In conclusion, our findings reveal strong expression of FXR in pancreatic cancer, and suggested that FXR may serve as an oncogenic factor that promotes pancreatic progression by collaborating with Sp1. This evidence concerns the gene SP1 and familial pancreatic carcinoma.